Immutep (NASDAQ: IMMP)
$2.31
(-7.2%)
-$0.18
Price as of April 15, 2024, 4:00 p.m. ET
Immutep Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Immutep Company Info
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.